Tag Archive for: DEST

Destiny Pharma appoints Dr Yuri Martina as CMO

Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri Martina as Chief Medical Officer Brighton, United Kingdom – 3rd May 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces the appointment of Dr. Yuri Martina as Chief Medical Officer (CMO). Read more

Destiny Pharma: Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme

Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme Phase 3 can use similar primary endpoint to the very successful Phase 2b clinical study New European report underpins clinical need and market opportunity of XF-73 Nasal Brighton, United Kingdom, 8 February 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]

Destiny Pharma Lancet Report

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important Lancet report highlights growing threat of Antimicrobial Resistance with over one million deaths per year Destiny Pharma’s XF platform is delivering effective drug candidates that also address the threat of AMR Brighton, United Kingdom, 21 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]

2021 and beyond with Destiny Pharma’s CEO, Neil Clark & CFO Shaun Claydon

Management of Destiny Pharma (DEST), the AIM listed infection prevention biotechnology company, offer an overview of the Company, their platform and their late stage clinical assets heading towards phase 3 trails. The team expand on the anti infective market, their COVID 19 program and the strength of their balance sheet. The Company finish with their […]